President Trump blames the Federal Reserve for its *crazy tight* interest rate hike.

Becky Berkman

2018-10-13 10:44:00 Sat ET

Dow Jones tumbles 3% or 831 points while NASDAQ tanks 4%, and this negative investor sentiment rips through most European and Asian stock markets in early-October 2018. President Trump blames the Federal Reserve for its *crazy tight* interest rate hike. However, this criticism may not be the main trigger for bearish massive stock sell-off. The relentless Sino-American trade impasse remains on the radar for stock market investors. Also, the 10-year Treasury bond yield rises above 3%, and then many institutional investors switch from stock bets to Treasury bond purchases.

Due to these unforeseen circumstances, the International Monetary Fund (IMF) downgrades global economic growth from 3.9% to 3.7% as of October 2018. This latter downgrade seems to trigger ubiquitous investor panic that manifests in the recent surge of the CBOE volatility index (VIX) well beyond 22 points.

Treasury Secretary Steven Mnuchin views the severe bloodbath from S&P 500 to NASDAQ as a normal stock market correction. Mnuchin considers this widespread stock market correction as part of the healthy fundamental recalibration primarily for tech titans such as Facebook, Apple, Microsoft, Google, Amazon, Netflix, and Twitter (FAMGANT). These tech titans exhibit prior stock market overvaluation in the interim period from late-2017 to early-2018.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

CEO overconfidence and corporate performance

Laura Hermes

2022-11-05 11:32:00 Saturday ET

CEO overconfidence and corporate performance

CEO overconfidence and corporate performance Malmendier and Tate (JFE 2008, JF 2005) argue that overconfident CEOs are more likely to initiate mergers an

+See More

American state attorneys general begin bipartisan antitrust investigations into Apple, Amazon, Facebook, and Google.

Charlene Vos

2019-10-21 10:35:00 Monday ET

American state attorneys general begin bipartisan antitrust investigations into Apple, Amazon, Facebook, and Google.

American state attorneys general begin bipartisan antitrust investigations into the market power and corporate behavior of central tech titans such as Apple

+See More

The great reversal of antitrust merger review in America

Monica McNeil

2023-10-07 10:24:00 Saturday ET

The great reversal of antitrust merger review in America

Thomas Philippon draws attention to greater antitrust scrutiny in light of the rise of market power and its economic ripple effects. Thomas Philippon (20

+See More

President Trump tweets that he asks the SEC to assess the practical implications of switching to a 6-month corporate disclosure cycle.

John Fourier

2018-08-17 11:45:00 Friday ET

President Trump tweets that he asks the SEC to assess the practical implications of switching to a 6-month corporate disclosure cycle.

In accordance with the extant corporate disclosure rules and requirements, all U.S. public corporations have to report their balance sheets, income statemen

+See More

Facebook, Twitter, and Google executives explain the scope of Russian interference in the U.S. 2016 presidential election.

Apple Boston

2017-09-19 05:34:00 Tuesday ET

Facebook, Twitter, and Google executives explain the scope of Russian interference in the U.S. 2016 presidential election.

Facebook, Twitter, and Google executives head before the Senate Judiciary Committee to explain the scope of Russian interference in the U.S. presidential el

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More